Trial Profile
A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2020
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2015 Primary endpoint has not been met.
- 07 Jul 2015 Results published in the Journal of Clinical Psychiatry.